CrushSCI.com
112.7平均天数
127.5中位天数
2最短天数
246最长天数
1372025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

156 天

Anatomy of periprostatic nerves and nerve-sparing strategy for radical prostatectomy

作者
Qiancheng Ma; Yan Liu; Yongzheng Han; Qiwei Chen; Deyong Yang展开收起
作者单位
1. Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China; 2. Dalian Medical University, Dalian, China; 3. Department of Surgery, Healinghands Clinic, Dalian, China展开收起
PDF源文件 DOI 网页
182 天

Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)

作者
Young Suk Kwon; Reena Kudchadker; Neil B. Desai; Raquibul Hannan; MinJae Lee; Ryan Mauck; Jennifer Tse; Kris Gaston; Tamara Dickinson; Shaghayegh Rezaie; Brad Hornberger; Daniel Yang; Maricruz Ibarra; Howard Morgan; Yang Kyun Park; Yesenia Gonzalez; Claus Roehrborn; Robert Timmerman; Solomon Woldu; Aurelie Garant展开收起
作者单位
1. Department of Radiation Oncology, University of Texas at Southwestern Medical Center, Dallas, USA; 2. Division of Clinical & Translational Sciences, McGovern Medical School, UTHealth Houston, Houston, USA; 3. Department of Urology, University of Texas at Southwestern Medical Center, Dallas, USA; 4. CARTI, Little Rock, USA展开收起
PDF源文件 DOI 网页
128 天

Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177 Lu-PSMA-617 therapy in advanced prostate cancer

作者
Ronit Juthani; Caiwei Zhong; Ali Tarhini; Miguel Muniz; Wanling Xie; Hailey Stoltenberg; Andrew Wolanski; Jolivette Ritzer; Xiao X. Wei; Heather Jacene; Daniel S. Childs; Praful Ravi展开收起
作者单位
1. St Vincent’s Hospital, Worcester, USA; 2. Dana-Farber Cancer Institute, Boston, USA; 3. Department of Oncology, Mayo Clinic, Rochester, USA展开收起
PDF源文件 DOI 网页
46 天

PRAISE-U: from pilot to program—what clinicians need to know from population-based screening for prostate cancer

作者
M. J. Roobol; R. C. N. van den Bergh; S. Collen; A. Chandran; H. Van Poppel展开收起
作者单位
1. Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; 2. European Association of Urology, Policy Office, Arnhem, The Netherlands; 3. International Agency for Research on Cancer/World Health Organization, Lyon, France; 4. Department of Urology, KU Leuven, Leuven, Belgium展开收起
PDF源文件 DOI 网页
246 天

Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study

作者
Rana R. McKay; Orsolya Lunacsek; Matthew J. Korn; Amit D. Raval展开收起
作者单位
1. Moores Cancer Center, University of California San Diego, La Jolla, USA; 2. Bayer HealthCare Pharmaceuticals, Whippany, USA展开收起
PDF源文件 DOI 网页
145 天

Prostate cancer worldwide: updated epidemiology, disparities, and screening implications

作者
Rui M. Bernardino; David-Dan Nguyen; Sigrid V. Carlsson; Giorgio Gandaglia; Zeyad Schwen; Nicolas A. Soputro; Mohamad Watfa; Abdulrahman Al-Bayati; Mohammad El Hussein; Rebecca Campbell; Karim Daher; Salim Younis; Jane Nguyen; Christopher Weight; Carlo La Vecchia; Alexandre R. Zlotta; Cosimo de Nunzio; Firas Abdollah; Jonathan Evan Shoag; Spyridon Basourakos; Frederico Ferronha; Andrea Cosenza; Christopher Wallis; Quoc-Dien Trinh; Neil Fleshner; Jihad Kaouk; Riccardo Autorino展开收起
作者单位
1. Glickman Urological Institute, Cleveland Clinic, Cleveland, USA; 2. Division of Urology, University of Toronto, Toronto, Canada; 3. Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany; 4. Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden; 5. Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; 6. Diagnostics Institute, Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, USA; 7. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; 8. Department of Urology, Sant’Andrea Hospital, ‘Sapienza’ University of Rome, Rome, Italy; 9. Vattikuti Urology Institute, Henry Ford Health System, Detroit, USA; 10. University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, USA; 11. Unidade Local Saúde São José, Lisbon, Portugal; 12. University of Pittsburgh School of Medicine, Pittsburgh, USA展开收起
PDF源文件 DOI 网页

FAQ

PROSTATE CANCER AND PROSTATIC DISEASES审稿要多久?

截至2026-11-18,CrushSCI 收录了 PROSTATE CANCER AND PROSTATIC DISEASES 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 2 天(Focal therapy for localized prostate cancer: not all that glitters is gold,2026-06-15 收稿,2026-06-17 录用),最慢一篇用了 246 天;平均 112.7 天,中位数 127.5 天。最快这篇的日期间隔异常短,建议点开原文核对。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。